Citius Pharmaceuticals (CTXR) Income from Non-Controlling Interests (2019 - 2026)

Citius Pharmaceuticals (CTXR) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$6.9 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 1056.07% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.3 million (down 769.15% YoY) and the FY2025 annual result came in at -$2.3 million, down 703.61% from the prior year.
• Income from Non-Controlling Interests slipped to -$6.9 million in Q1 2026, from -$1.2 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of -$414000.0 in Q2 2025 to a low of -$6.9 million in Q1 2026.
• A 3-year average of -$1.7 million and a median of -$689679.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
• Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests sank 128.68% — and 2026, when it plunged 1056.07%.
• Tracing CTXR's Income from Non-Controlling Interests over 3 years: stood at -$513000.0 in 2024, then slumped by 128.68% to -$1.2 million in 2025, then sank by 486.36% to -$6.9 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at -$6.9 million (Q1 2026), -$1.2 million (Q4 2025), and -$784358.0 (Q3 2025), per Business Quant data.